PGFC
Role of PPARgamma in the interstitial fluid volume regulation and contribution to cardiovascular complications of TZDs
| Coordinatore | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
Organization address
address: C/ MELCHOR FERNANDEZ ALMAGRO 3 contact info |
| Nazionalità Coordinatore | Spain [ES] |
| Totale costo | 154˙102 € |
| EC contributo | 154˙102 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-IEF-2008 |
| Funding Scheme | MC-IEF |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-10-01 - 2011-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
Organization address
address: C/ MELCHOR FERNANDEZ ALMAGRO 3 contact info |
ES (MADRID) | coordinator | 154˙102.06 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Thiazolidinediones (TZDs) are clinically proven insulin sensitizers with anti-inflammatory benefits used in the therapy of type 2 diabetes mellitus (T2DM) and atherosclerosis. TZDs can activate a transcription factor, the peroxisome proliferator-activated receptor gamma (PPARg). PPARg regulates expression of several genes involved in inflammatory pathways, lipid transport and carbohydrate metabolism. Antidiabetic effects of TZDs have been coupled to macrophages, since tissue macrophages can produce inflammatory mediators which can reduce insulin sensitivity leading to T2DM and its cardiovascular complications. Administration of TZDs spreaded rapidly recently, although serious secondary effects as fluid retention and ischemic heart disease have questioned the clear benefits of non-selective PPARï§ activation by TZDs in the medication of T2DM and related disorders. Kidney PPARï§ positively regulates sodium and water resorbtion, therefore TZD-induced fluid retention can be due to the activation of PPARγ in the kidney collecting ducts. Fluid retention can lead to backward heart failure, therefore we think that kidney PPARï§ is the origin of unwanted cardiac TZD effects. To test this novel hypothesis we propose a cross-disciplinary research project involving molecular genetics, in vivo imaging, and gene engineered animal models targeting the molecular mechanisms behind the cardiovascular complications of TZDs. We will determine also the contribution of tissue specific PPARï§ mutations to water retention and ischemic heart disease. Molecular mechanisms behind T2DM and its cardiovascular complications are among the most important and timeliness research areas in Europe, due to the growing T2DM prevalence. Understanding TZD side effects will contribute to new treatment strategies of T2DM. The success of this proposal will increase European competitiveness and will produce long term synergies and structuring community research effects.'